Clinical Study of JS007 in Patients With Advanced Solid Tumors

Phase 1 Unknown 42 enrolled Shanghai Junshi Bioscience Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is an open label, phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, immunogenicity and preliminary efficacy of JS007 in the patients with advanced solid tumors who have progressed after standard of care, or lack of effective standard therapeutic regimen. This study is divided into two periods: dose escalation period, dose expansion period.

Timeline

Start: 2021-11-17
Primary completion: 2022-09-20
Completion: 2022-09-20

Publications

Zhou C, Jiang J, Xiang X, Liu H, Wu G, Zeng R, Lu T, Zhang M, Shen Y, Hong M, Zhang J. Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors. Exp Hematol Oncol. 2024 Oct 1;13(1):98. doi: 10.1186/s40164-024-00567-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JS007	Unknown	0.03 mg/kg	Intravenous
Subject	JS007	Unknown	0.3 mg/kg	Intravenous
Subject	JS007	Unknown	1 mg/kg	Intravenous
Subject	JS007	Unknown	3 mg/kg	Intravenous
Subject	JS007	Unknown	10 mg/kg	Intravenous

Indications

No indication recorded.